|
If there are problems with how this message is displayed, click here to view it in a web browser.
|
If there are problems with how this message is displayed, click here to view it in a web browser.
|
|
|
body-urg-004
| Patients with uncontrolled seizures have an increased risk of comorbidities1*† |
 |
Cardiac and
Metabolic |
| 1.5-2x |
more likely to have atrial fibrillation (AFib) |
|
 |
Neuro-psychiatric |
| 3x |
more likely to have non-epileptic seizures |
|
 |
Neurologic |
| 1.5-2x |
more likely to have brain trauma |
| 1.5-2x |
more likely to develop dementia/Alzheimer’s |
| 1.5-2x |
more likely to have a stroke |
|
|
Cardiac and
Metabolic |
|
1.5-2x |
more likely to have atrial fibrillation (AFib) |
|
|
Neuro-psychiatric |
|
3x |
more likely to have non-epileptic seizures |
|
|
Neurologic |
|
| 1.5-2x |
more likely to have brain trauma |
| 1.5-2x |
more likely to develop dementia/Alzheimer’s |
| 1.5-2x |
more likely to have a stroke |
|
|
|
| * |
Incidence of comorbidities in patients with uncontrolled vs controlled epilepsy following initiation of first-line and third-line ASM. |
| † |
Uncontrolled epilepsy was defined by ≥1 of the following events: seizure-related inpatient visit, seizure-related emergency room visit, or new ASM line of therapy initiation. |
|
ASM=anti-seizure medication. |
|
|
|
|
body-eff-005
| Switch on XCOPRI sooner |
 |
| #1 branded ASM |
| prescribed by epileptologists* |
 |
| Over 275,000 patients |
| prescribed worldwide and counting† |
 |
| Copay comparable to generics‡ |
| 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI§ |
 |
| 10+ years of clinical trial and real-world experience |
| Well-studied safety with 5-year retention data1,2 |
|
| #1 branded ASM |
| prescribed by epileptologists* |
|
|
|
| Over 275,000 patients prescribed worldwide and counting† |
|
|
|
| Copay comparable to generics‡ |
| 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI§ |
|
|
|
| 10+ years of clinical trial and real-world experience |
| Well-studied safety with 5-year retention data1,2 |
|
|
|
| * |
By NBRx, as of July 2025. |
| † |
Worldwide new-to-brand cenobamate prescriptions as of December 2025. Source: IQVIA. |
| ‡ |
IQVIA, Patient Cost Disclosure 12 months ending April 2025. |
| § |
Managed Markets Insight & Technology, LLC, database as of July 2025. |
|
|
|
|
body-tol-002
| Cognition with XCOPRI |
 |
| Based on a post hoc analysis of pooled populations across phase 2 and phase 3 studies |
| Rates of cognitive TEAEs observed with XCOPRI were 2.3% vs 0.9% with placebo.1* |
|
| Based on a post hoc analysis of pooled populations across phase 2 and phase 3 studies |
| Rates of cognitive TEAEs observed with XCOPRI were 2.3% vs 0.9% with placebo.1* |
|
|
|
| Limitations: Cognitive symptoms were evaluated using non-standardized measures including spontaneous patient self-reporting, which may have led to underreporting of mild or intermittent symptoms. Baseline cognitive comorbidities were assessed retrospectively and could not be directly compared with TEAEs. Potential confounding effects from concomitant anti-seizure medications further limit interpretation of cognitive findings. |
| * |
Patients with focal epilepsy were assessed on memory impairment, word-finding difficulty, mathematical difficulty, and disturbances in attention. |
|
TEAEs=treatment-emergent adverse events. |
|
|
|
|
body-tol-003
| Weight with XCOPRI |
 |
| Low rates of weight change reported with XCOPRI in pivotal trials1 |
| XCOPRI (3/442) vs placebo (0/216) |
|
| Low rates of weight change reported with XCOPRI in pivotal trials1 |
| XCOPRI (3/442) vs placebo (0/216) |
|
|
|
|
|
|
body-dos-001
| Overview of dosing with XCOPRI1 |
 |
| Convenient once-daily dosing and a half-life of 50-60 hours |
|
| Take any time, whole or crushed, with or without food |
|
| Can be taken as monotherapy or adjunctive therapy |
|
| Convenient once-daily dosing and a half-life of 50-60 hours |
|
|
|
| Take any time, whole or crushed, with or without food |
|
|
|
| Can be taken as monotherapy or adjunctive therapy |
|
|
|
| Liver function tests should be conducted prior to starting XCOPRI to establish baseline liver function if results are not available from the past 3 months. |
| 200 mg is the maximum dosage for patients with mild or moderate hepatic impairment. XCOPRI is not recommended for use in patients with severe hepatic impairment. |
|
|
|
body-gen-001
| XCOPRI resources and downloadable tools for your patients and practice |
 |
| Expert insights |
| Hear from your peers who have switched on the power of XCOPRI—and are seeing meaningful results. |
|
|
|
| Expert insights |
| Hear from your peers who have switched on the power of XCOPRI—and are seeing meaningful results. |
|
|
|
|
 |
| XCOPRI patients |
| Real patients. Real progress. See how XCOPRI is helping light the way forward to fewer seizures. |
|
|
|
| XCOPRI patients |
| Real patients. Real progress. See how XCOPRI is helping light the way forward to fewer seizures. |
|
|
|
|
 |
| Downloadable PDFs |
| Our clinical resources and patient support tools are designed to help you make informed decisions, every step of the way. |
|
|
|
| Downloadable PDFs |
| Our clinical resources and patient support tools are designed to help you make informed decisions, every step of the way. |
|
|
|
|
 |
| FAQs |
| Explore answers to common questions about XCOPRI. |
|
|
|
| FAQs |
| Explore answers to common questions about XCOPRI. |
|
|
|
|
|
|
|